It’s Show Time Klone 4.0 is simmering on the horizon

Created on:2020-09-02 12:00



September 2nd,2020 Press Release


"Made in Changping" Young Students Training Camp Visited Great Bay Bio


[2020/9/2, Dongguan]At 9am, September 8th EST, Michael Chen, CEO of Great Bay Bio will present on the Medivest Conference, unveiling our Klone 4.0 platform.


Great Bay Bio is an innovative, AI-bioproduction technology company poised to disrupt the biological drug development industry by means of its AI-enabled multi-platform. The company will also seek to engage a "blue ocean" approach to apply its machine learning technologies to CAR-T, molecular diagnostics, mAb sequencing, and further laboratory-based applications.  Great Bay Bio aims to work with world-class institutions, drug innovators and industry collaborators as it prepares for the commercial launch of its cell line and cell culture media applications, Klone4.0 and AlfaMedX, this fall. 


Klone4.0 uses AI algorithms, supercomputer processors and robotic cell selectors that can be placed on site, has demonstrated a unique ability to reduce cell line development time by as much as 80%. By eliminating many of the pain points involved in cell selection, it can quickly identify high expressing cells and thereby produce a higher quality cell line. Similarly, AlfaMedX shortens the cell media formulation process by 80% and provides drug innovators with the added benefits of control and confidentiality of their own cell culture media. 


About Great Bay Bio

Headquartered in Hong Kong, GBB is a high-tech enterprise dedicated to applying artificial intelligence and other cutting-edge technologies to CMC (Chemistry, Manufacturing, Control) for development of biopharmaceuticals and other blue ocean bio-products (such as cell therapy), ultimately solving numerous pain points of CMC development, including high failure rates, long development timeline and high costs. Since the company’s establishment, it has obtained massive data from conventional biologics development in its 3100 m2 CMC facilities in Dongguan, PRC. With over RMB 300M investment, the facilities bolster advance equipment from world-renowned manufacturers. GBB has also successfully brought a number of biologic products to NDA stage, some of which are classified as national class I innovative drugs. Currently, the company has created the intelligent centralized database, where deep learning is being performed to create next generation AI-enabled CMC platforms. To learn more, please visit


PR Contact: Miss Liu 


Home    News    It’s Show Time Klone 4.0 is simmering on the horizon